Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

COMPASS Pathways plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #BIOTECH--COMPASS PATHWAYS PLC (NASDAQ: CMPS), A BIOTECHNOLOGY COMPANY DEDICATED TO UNLOCKING URGENTLY NEEDED NEW TREATMENT OPTIONS IN MENTAL HEALTH CARE, ANNOUNCED TODAY THAT IT WILL RELEASE FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST HALF ENDED JUNE 30, 2026, ON AUGUST 5, 2026. COMPASS MANAGEMENT WILL HOST A CONFERENCE CALL AT 8:00 AM ET (1:00 PM UK) ON AUGUST 5, 2026. A LIVE WEBCAST OF THE CALL WILL BE AVAILABLE ON THE COMPASS PATHWAYS WEBSITE AT: HTTPS://EVE.

COMPASS PATHWAYS TO ANNOUNCE SECOND QUARTER AND FIRST HALF 2026 FINANCIAL RESULTS ON AUGUST 5, 2026

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #BIOTECH--COMPASS PATHWAYS PLC (NASDAQ: CMPS), A BIOTECHNOLOGY COMPANY DEDICATED TO ACCELERATING PATIENT ACCESS TO EVIDENCE-BASED INNOVATION IN MENTAL HEALTH, TODAY ANNOUNCED THE PUBLICATION OF A POST-HOC ANALYSIS OF SUPPORT METHODS USED IN AN OPEN-LABEL PHASE 2 STUDY OF INVESTIGATIONAL COMP360 SYNTHETIC PSILOCYBIN TREATMENT IN PATIENTS WITH POST-TRAUMATIC STRESS DISORDER (PTSD). DOCUMENTED SPEECH PRODUCTION BETWEEN PARTICIPANTS AND SUPPORT PROVIDERS DURING TREATMENT A.

COMPASS PATHWAYS ANNOUNCES PUBLICATION OF POST-HOC ANALYSIS DEMONSTRATING DISTINCTION OF COMP360 TRIAL MONITORING & SUPPORT FROM PSYCHOTHERAPY

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #BIOTECH--COMPASS PATHWAYS PLC (NASDAQ: CMPS), A BIOTECHNOLOGY COMPANY DEDICATED TO ACCELERATING PATIENT ACCESS TO EVIDENCE-BASED INNOVATION, ANNOUNCED TODAY THE 26-WEEK RESULTS (PART B) FROM ITS SECOND ONGOING PHASE 3 COMP006 TRIAL OF COMP360, A SYNTHETIC, PROPRIETARY FORMULATION OF PSILOCYBIN, FOR TREATMENT-RESISTANT DEPRESSION (TRD) WHICH CONFIRM COMP360'S RAPID ONSET AND DURABLE PROFILE. THE 26-WEEK FINDINGS IN NEARLY 600 PATIENTS BUILD ON PREVIOUSLY REPORTED RESUL.

COMPASS PATHWAYS ANNOUNCES SIX-MONTH DATA FROM SECOND PHASE 3 TRIAL CONFIRMING RAPID AND DURABLE PROFILE

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #BIOTECH--COMPASS PATHWAYS PLC (NASDAQ: CMPS), A BIOTECHNOLOGY COMPANY DEDICATED TO ACCELERATING PATIENT ACCESS TO EVIDENCE-BASED INNOVATION IN MENTAL HEALTH, ANNOUNCED TODAY THAT COMPASS GRANTED EQUITY AWARDS UNDER THE COMPASS PATHWAYS PLC 2026 INDUCEMENT PLAN TO EIGHT NEWLY HIRED NON-EXECUTIVE EMPLOYEES. THE EQUITY AWARDS WERE GRANTED ON JULY 1, 2026 AND CONSISTED OF OPTIONS TO PURCHASE AN AGGREGATE OF 63,685 SHARES AND RESTRICTED SHARE UNITS OR, IN THE CASE OF EMPLO.

COMPASS PATHWAYS ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

ISSUED ON BEHALF OF HELUS PHARMA HELUS PHARMA (NASDAQ: HELP) (CBOE CA: HELP), THE COMMERCIAL OPERATING NAME OF CYBIN INC., SAYS ITS APPROACH PHASE 3 TRIAL OF HLP003 FOR ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER HAS SURPASSED 86% ENROLLMENT, KEEPING THE FDA BREAKTHROUGH-DESIGNATED PROGRAM ON TRACK FOR A TOPLINE DATA READOUT IN Q4 2026. NEW YORK AND TORONTO, JUNE 26, 2026 /PRNEWSWIRE/ -- USA NEWS GROUP NEWS COMMENTARY, IN DRUG DEVELOPMENT, ENROLLMENT IS THE QUIET VARIABLE THAT DECIDES WHETHER A PROMISING THERAPY EVER REACHES A DATA READOUT ON SCHEDULE.

A BREAKTHROUGH-DESIGNATED DEPRESSION DRUG IS 86% THROUGH ITS PHASE 3, WITH TOPLINE DATA DUE THIS YEAR

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #BIOTECH--COMPASS PATHWAYS PLC (NASDAQ: CMPS), A BIOTECHNOLOGY COMPANY DEDICATED TO ACCELERATING PATIENT ACCESS TO EVIDENCE-BASED INNOVATION IN MENTAL HEALTH, ANNOUNCED TODAY THAT COMPASS GRANTED EQUITY AWARDS UNDER THE COMPASS PATHWAYS PLC 2026 INDUCEMENT PLAN TO SEVENTEEN NEWLY HIRED NON-EXECUTIVE EMPLOYEES. THE EQUITY AWARDS WERE GRANTED ON JUNE 1, 2026 AND CONSISTED OF OPTIONS TO PURCHASE AN AGGREGATE OF 157,000 SHARES AND RESTRICTED SHARE UNITS OR, IN THE CASE OF.

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #BIOTECH--COMPASS PATHWAYS PLC (NASDAQ: CMPS), A BIOTECHNOLOGY COMPANY DEDICATED TO ACCELERATING PATIENT ACCESS TO EVIDENCE-BASED INNOVATION IN MENTAL HEALTH, TODAY ANNOUNCED THE ELECTION OF KATHLEEN TREGONING TO ITS BOARD OF DIRECTORS AT THE ANNUAL GENERAL MEETING OF SHAREHOLDERS. MS. TREGONING IS EXPECTED TO SERVE ON THE COMPENSATION AND LEADERSHIP DEVELOPMENT COMMITTEE AND THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE. SHE BRINGS EXTENSIVE EXPERIENCE GUIDING BIO.

COMPASS PATHWAYS ELECTS KATHLEEN TREGONING TO BOARD OF DIRECTORS

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #BIOTECH--COMPASS PATHWAYS PLC (NASDAQ: CMPS), A BIOTECHNOLOGY COMPANY DEDICATED TO ACCELERATING PATIENT ACCESS TO EVIDENCE-BASED INNOVATION IN MENTAL HEALTH, ANNOUNCED TODAY THAT MANAGEMENT WILL ATTEND THE RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE ON MAY 19-20, 2026 AND WILL PARTICIPATE IN A FIRESIDE CHAT ON MAY 19 AT 10:00AM ET. A LIVE AUDIO WEBCAST OF THIS EVENT WILL BE ACCESSIBLE FROM THE EVENTS PAGE OF THE INVESTORS SECTION OF THE COMPASS WEBSITE. A REPLA.

COMPASS PATHWAYS TO PARTICIPATE IN RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE ON MAY 19-20, 2026

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #BIOTECH--COMPASS PATHWAYS PLC (NASDAQ: CMPS), A BIOTECHNOLOGY COMPANY DEDICATED TO ACCELERATING PATIENT ACCESS TO EVIDENCE-BASED INNOVATION IN MENTAL HEALTH, TODAY REPORTED FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS. WITH REGULATORY ACCELERATION UNFOLDING, WE ARE WORKING DILIGENTLY TOWARDS OUR GOAL OF COMPLETING THE FILING OF A ROBUST CLINICAL PACKAGE BY Q4 AND SECURING COMP360 APPROVAL, SAID KABIR NATH, CHIEF EXECUTIVE OFFICER OF COMPASS PATHWAYS.

COMPASS PATHWAYS ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #BIOTECH--COMPASS PATHWAYS PLC (NASDAQ: CMPS), A BIOTECHNOLOGY COMPANY DEDICATED TO ACCELERATING PATIENT ACCESS TO EVIDENCE-BASED INNOVATION IN MENTAL HEALTH, ANNOUNCED TODAY THAT IT WILL RELEASE FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDE AN UPDATE ON RECENT DEVELOPMENTS, ON MAY 13, 2026. COMPASS MANAGEMENT WILL HOST A CONFERENCE CALL AT 8:00 AM ET (1:00 PM UK) ON MAY 13, 2026. A LIVE WEBCAST OF THE CALL WILL BE AVAILABLE ON THE COMPASS P.

COMPASS Pathways plc

CMPS

Price

Financial Reports

No items found.

Press Releases

COMPASS Pathways plc

CMPS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CMPS